Idorsia Ltd (IDRSF)

2.0300 0.0000 (0.00%) At close: 02:44PM EDT

Idorsia Ltd

Hegenheimermattweg 91
Allschwil 4123
Switzerland
41 58 844 10 10
https://www.idorsia.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Jean-Paul Clozel M.D.	CEO & Executive Director	1.51M	N/A	1955
Mr. André C. Muller	Executive VP & CFO	N/A	N/A	1963
Dr. Martine Clozel	Executive VP & Chief Scientific Officer	N/A	N/A	1955
Mr. Andrew C. Weiss	Senior VP and Head of Investor Relations & Corporate Communications	N/A	N/A	1968
Mr. Julien Gander L.L.M.	Senior VP, Group General Counsel & Company Secretary	N/A	N/A	1979
Mr. Alexander Khatuntsev	Senior VP & Head of Global Human Resources	N/A	N/A	1978
Dr. Guy Braunstein M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1956
Mr. Olivier Lambert	Senior VP & Head of Technical Operations	N/A	N/A	1966
Mr. Markus A. Riederer	Senior VP & Head of Drug Discovery Biology	N/A	N/A	1962
Mr. Christoph Boss	Senior VP & Head of Drug Discovery Chemistry	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Corporate governance

Idorsia Ltd’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 10; Board: 2; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.